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as the basic components of research and development. Similarly, natural products are chemically tailored
and modiﬁed based upon their structural and biological properties. To some extent, the modiﬁcation of
natural products is quite different from de novo structure-based drug discovery. This review describes the
general strategies and principles for the modiﬁcation of natural products to drugs, as illustrated by several
successful medicines that originated from natural products.
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Zongru Guo21. Introduction
The species diversity of plants, animals, microorganisms, and
marine organisms results in a multitude of secondary metabolites
with diverse chemical structures, which have played, and will
continue to play, a vital role in the drug discovery and develop-
ment process. Indeed, the diversity of plant-based systems has
provided an enormous number of lead compounds in healthcare.
Similarly, the application of microorganismal metabolites as
chemotherapeutics has created the ﬁeld of antibiotics for anti-
infectious and anti-cancer therapies. Many scaffolds of compounds
obtained from marine microorganisms and phytoplankton, algae
sponges for example, similarly have provided more recent leads
for drug discovery and development. And ﬁnally, endogenous
neurotransmitters and active peptides from human beings and
animals constitute an important source for drug research.
From the standpoint of drug innovation, it is necessary to
modify natural product structures, because the aim in generation of
secondary metabolites by organisms is to protect themselves from
natural enemies as well as the environment. Natural product–based
drug discovery is characterized with a starting-point of an active
compound that necessitates “tailor-made” or individualized
manipulation of the structure so as to reach a drug criterion. In
this context, the molecular modiﬁcation of natural products is quite
different from the strategy of structure-based drug discovery. ThisFigure 1 The general featu
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10.1016/j.apsb.2016.06.003article describes some aspects and principles of modifying natural
compounds to lead to successful medicines.2. The general features of natural products
Natural products, from simple salicylic acid to complex vancomy-
cin, encompass compounds with various molecular sizes, chemo-
types, and structural features that can be summarized as follows.2.1. Structural diversity and complexity
Natural products are characterized by their structural diversity,
much of which is even unexpected by chemists. For example in
Fig. 1A, anti-malarial artemisinin (1) is composed of a fused
trioxene system with peroxy, lactone, cyclic acetal and ketal
moieties. The individual scaffold of artemisinin maintains both
the oxidative potential as well as chemical stability. The well-
known anti-cancer drug paclitaxel (2) possesses a 6,8,6,4-tetra-
cycle-fused skeleton linking functional groups at special positions
that ensures binding to tubulin. The non-peptide cholecystokinin
(CCK) antagonist asperlicin (3), originated from extracts of
Aspergillus alliaceus, is a chemically-complex molecule with a
quinazolinone-fused benzodiazepine core.res of natural products.
r medical use. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/
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products constitute the prerequisite for strong binding to targets,
yet also increase the probability of additional interactions with
biological molecules, as well as the difﬁculty in chemical
synthesis. However, from the viewpoint of drug research, many
structures of natural products exist as “redundant atoms”, which do
not participate in the binding to target and convey disadvantageous
effects on the physico-chemical, pharmacokinetic and biopharma-
ceutical properties. Therefore, those unnecessary moieties should
be appropriately removed from lead compounds in structural
modiﬁcations, raising the ligand efﬁciency (LE) of molecules1.
LE is a measure of the binding energy per unit of mass for a given
compound relative to its molecular target. High values of LE imply
fewer unnecessary atoms relative to target-binding. This parameter
is routinely used as one of the guiding factors in the early stages of
lead optimization.
2.2. More sp3 carbon atoms and less nitrogen and halogen
elements
Most natural products are composed of more sp3-hybrid carbons
than sp2 carbons, making the tetrahedron carbons connect to each
other to form ﬂexible chain or cyclic structures. For example in
Fig. 1B, both the immunological regulator tacrolimus (4) and the
anti-cancer compound epothilone B (5) are macrolides containing
many saturated carbon atoms. Another immune-regulator, ISP-1
(6), isolated from Cordyceps sinensis Sacc, is a linear and ﬂexible
molecule. An exception is the anti-cancer drug camptothecin (7), a
fused and conjugated aromatic system with multiple sp2 carbons.
Most natural products consist of carbon, hydrogen, oxygen
atoms but limited nitrogen incorporation, probably due to the weak
nitrogen-ﬁxing ability of microorganisms and plants (except
Leguminoceae plants which produce alkaloids as secondary
metabolites). These features provide various options for introdu-
cing nitrogen atoms during modiﬁcation. Nitrogen is a versatile
atom in many aspects, having a stronger nucleophilic property than
carbon and oxygen, providing 3- or 5-valence bond, forming salts
for alkaline amines or being a neutral amide, building hetero-
cycles, aromatic and fused compounds, being able to be a terminal
group or to serve as a linker to connect other groups. Therefore,
introduction or modiﬁcation of various nitrogen atoms is an
important molecular operation in lead compound optimization.
Natural products rarely contain halogen atoms, although marine
products sometimes incorporate a bromine atom.
2.3. Existence of chiral centers and stereochemistry
Natural products are synthesized in organisms by enzymatic
catalysis, which take place with stereochemical speciﬁcity, yield-
ing stereospeciﬁc compounds with chiral centers, chiral axes, or
cis/trans-conﬁgurations. These asymmetrical factors usually con-
vey a critical contribution to pharmacological actions. However,
those chiral centers not participating in the binding to targets are
unnecessary. In manipulating or simplifying natural products the
unnecessary chirality and stereochemistry have to be removed as
much as possible, as compounds that lack chirality make the
simpliﬁed analogs easy and economical to synthesize. For example
in Fig. 1C, the old analgesic morphine (8) contains 21 heavy atoms
(non-hydrogen atoms), 5 fused rings, and 5 chiral carbon atoms.
The synthetic analgesic drug fentanyl (9) derived from morphine is
a much simpler non-chiral molecule.Please cite this article as: Guo Zongru. The modiﬁcation of natural products fo
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3.1. Individualized manipulation based on the molecular size
and complexity
For large and complicated natural products, simpliﬁed operations
are normally carried out to eliminate structurally-unnecessary
factors. Molecular dissection is a useful method. The linear
molecules or peptides might be sheared along the chain consecu-
tively. For compounds with fused rings, the scaffolds could be
segmented into four quadrants to separately modify the structures
or groups. Maintaining the structure-activity relationship (SAR) is
absolutely necessary. Fig. 2A illustrates the SAR obtained from
modifying the paclitaxel (2) molecule.
The long-known alkaloid cocaine (10) was historically useful as
a topical anesthetic in eye and nasal surgery, yet the major
disadvantages of this use are cocaine's apostrophe intense vasocon-
strictor activity and potential for cardiovascular toxicity. Cocaine
has since been largely modiﬁed and simpliﬁed for synthetic local
anesthetics, such as procaine (11), tetracaine (12) and lidocaine (13)
(Fig. 2B).
Another natural product, physostigmine (14, Fig. 2C), is a
parasympathomimetic alkaloid, speciﬁcally, a reversible cholines-
terase inhibitor. Because of the chemical instability in vivo,
physostigmine was modiﬁed to simple and non-chiral compounds,
such as pyridostigmine bromide (15) and neostigmine bromide
(16, Fig. 2C). Unlike physostigmine, which is a tertiary amine,
these synthetic quaternary ammonium salts penetrate the central
nervous system poorly and have a lower propensity to cause
adverse effects such as orthostatic hypotension, while improving
muscle tone in patients with myasthenia gravis.
Analog syntheses are usually performed for natural leads with
appropriate molecular size. Using the principles of medicinal
chemistry, such as bio-isosterism, chain-ring exchange, privileged
structure and scaffold-hopping, new analogs are generated with
superior properties and compound novelty.
Compounds with small size have structural space to add atoms,
groups, or moieties, so that for example, introducing a hydrogen
donor or acceptor may increase the afﬁnity to receptors, or adding
solubilizing groups raises the solubility or modulates the partition
property to beneﬁt or avoid crossing the blood brain barrier.
3.2. Analyzing SAR and designing novel structures
In the absence of information on target structures, classical
medicinal chemistry methods are normally applied to the mod-
iﬁcation of natural products. SARs or quantitative SAR (QSAR)
are explored to reveal and assign the pharmacophores, which guide
the design of novel compounds with simpliﬁed or different
scaffolds. Based upon the SAR of paclitaxel, two semi-synthetic
analogs docetaxel (17) and cabazitaxel (18) have been launched
(Fig. 2D), the modiﬁcations of which are restricted at “south-west”
and “north-east” areas of the molecule.
3.3. Industrialized syntheses and protecting resources and
environments
Achievement of total synthesis for natural products has multiple
advantages: (a) to authenticate chemical structures; (b) to provide a
series of intermediates for evaluating activities, which usually
contain the identical pharmacophoric features as the originalr medical use. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/
Figure 2 Modiﬁcation strategies for natural products.
Zongru Guo4compounds and become simpliﬁed analogs; (c) to provide a basis
for industrialized production in scale-up; (d) to protect the natural
resources and environment.3.4. Removal of unnecessary chiral centers
Chirality in drug molecules yields diploid characteristics. The
positive side involves an increase of activity strength and selectivity
because of the appropriate binding to sterically-complementary and
asymmetrical targets. The negative side is the difﬁculty in synthesis,
separation, and resolution of single eutomers. In fact, not all chiral
centers in natural products are necessary for binding and activity.
The redundant chiral factors should be removed in modiﬁcations as
described later.4. Key points in structural modulation of natural products
The ﬁnal aim of modifying natural products is to develop active
compounds into medicines. All aspects of pharmacological,
toxicological, and druggable properties are included in the process
of modiﬁcation. Based on the adequacy of activity, safety,
pharmacokinetics, or physico-chemical aspects, purposive modiﬁ-
cations are performed as follows: (a) raising the activity strength
and selectivity; (b) improving solubility and partition property;
(c) increasing metabolic and chemical stability; (d) modulating
pharmacokinetic parameters (ADME); (e) removing or alleviating
toxicity and adverse reactions; (f) gaining novelty and intellectual
property.Please cite this article as: Guo Zongru. The modiﬁcation of natural products fo
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5.1. Simplifying structures
Natural products with a large size and complex structure are
unfavorable for solubility, absorption and metabolism. One of the
modiﬁcation principles is to decrease the molecular size and to
eliminate the unnecessary functional groups.5.1.1. From halichondrin B to eribulin
Halichondrin B (19, Fig. 3), a marine natural product, was originally
isolated from a Japanese rare marine sponge (Halichondria okadai).
It is a large polyether macrolide with MW 1109, and reported to
have strong anticancer activity against murine cancer cells both
in vitro and in vivo. While antiproliferative patterns of halichondrin
B were found to be similar to those of other antitubulin drugs, its
biochemical mechanism of interaction with tubulin is distinct from
all other known classes of antitubulin agents.
Halichondrin B contains 32 chiral carbon atoms distributed at
polyether and macrolide moieties 18 and 12, respectively. Poly-
ether and macrolide components are connected through C29 and
C30 to form a fused macrocyclic compound. One of the junctions,
C30, links a lactone group, which is easily hydrolyzed to release
the macrolide and lose the activity, owing to the alteration in the
conformation and spatial disposition of functional groups.
Kishi et al. 2 of Havard University systematically investigated
the total synthesis of halichondrin B. During the total synthesis
they adopted a strategy of simplifying the structure. Comparing the
repeated ethereal linkages of the polyether moiety to the multi-r medical use. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/
Figure 3 Simplifying structures from halichondrin B to eribulin.
Scheme 1 The ﬁnal coupling reactions of eribulin.
The modiﬁcation of natural products for medical use 5functional groups of the macrolide portion, the researchers
concentrated on synthesizing the latter. Two critical points are
modiﬁed in the synthesis of the macrolide: one is to replace the
oxygen atom of the lactone linkage with a methylene group, not
only to avoid the hydrolysis of the ester group linkage but also to
keep the conformation unchanged; the other is to introduce a
solubilizing group such as an amino group at the terminal of the
side chain in order to increase solubility while forming a salt2.
From 180 synthesized target compounds, eribulin (20, Fig. 3)
was found to be an optimal candidate and as a mesylate salt used
in clinic trials3. Eribulin was approved by the US Food and Drug
Administration (FDA) in 2010 to treat the patients with metastatic
breast cancer.
Structurally, eribulin is a most complex drug by organic
synthesis. There are nineteen chiral carbon atoms in the molecule.
Through a 62-step reaction, eribulin is synthesized from simple
organic starting materials. The synthetic scale-up of eribulin from
microgram to multi-gram quantities is attributable to a ten-year
technological study. The key coupling reactions include formation
of the C30a to C1 carbon–carbon bond and macrocyclic ring
closure through an intramolecular Nozaki–Hiyama–Kishi reaction,
which is brieﬂy shown in Scheme 14.
5.1.2. From myriocin to ﬁngolimod
The natural product myriocin (21, ISP-1, Fig. 4), a secondary
metabolite isolated from the fungus Isaria sinclairii, possessesPlease cite this article as: Guo Zongru. The modiﬁcation of natural products fo
10.1016/j.apsb.2016.06.003immuno-modulating activity ten times stronger than that of cephlos-
porin A in vitro and in vivo5. There exist 3 chiral carbon atoms and a
trans double bond in compound 21. In addition, the existence of
amino and carboxyl groups makes myriocin a zwitter ion at pH 7.4,
which is disadvantageous to absorption in vivo. The aim of modifying
compound 21 is to simplify the structure: alleviating the chiral
centers, raising activity strength and selectivity, and improving the
pharmacokinetic properties. Through a systematic examination of
each functional groups and study of the structure-activity relationship,
it was established that the C14 carbonyl group and the Δ6 double
bond are unnecessary for binding to the receptor. Three chiral carbon
atoms exhibit no stereo-speciﬁcity necessary for activity. The polar
groups and the molecular size and shape are critical factors.
Myriocin structurally resembles sphingosine (22, Fig. 4), and
was later identiﬁed to be a modulator of the sphingosine-1-
phosphate receptor6. Compound 23 (Fig. 4) reached the criterion
of drug candidate, named ﬁngolimod and entered the development
phase7. Fingolimod is a linear symmetrical molecule lacking chiral
and stereochemical factors. Insertion of a phenyl group to take the
place of some saturated carbon atoms in the aliphatic chain
partially reduces the molecular ﬂexibility and makes chemical
synthesis more facile. The position of the phenyl group in the
aliphatic chain conveys a signiﬁcant effect on the activity,
indicating that the molecular shape and conformation play an
important role. Fingolimod is the ﬁrst oral disease-modifying drug
approved by the US FDA in 2010 to reduce relapses and delayr medical use. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/
Figure 4 Simplifying structures from myriocin to ﬁngolimod.
Figure 5 Simplifying structures from schizandrin C to DDB and bicyclol.
Zongru Guo6disability progression in patients with relapsing forms of multiple
sclerosis. As a prodrug, one of the hydroxyl groups in ﬁngolimod
is phosphorylated by sphingosine kinases in the cell to yield the
active form, ﬁngolimod-1-phosphate (24, Fig. 4), which was
developed as a new molecular entity.
5.1.3. From schizandrin C to diphenyl bicarboxylate (DDB) and
bicyclol
It was reported that the Chinese traditional medicine Schizandra
sinensis may improve liver function and reduce symptoms of
patients infected with viral hepatitis B. Schizandrin C (25, Fig. 5),
one of the lignins isolated from fruits of Schizandra, promotes
hepatic anabolism and induces the activation of liver microsomal
cytochromes P-450, as well as alters the metabolism of the
carcinogen benzopyrene and its binding to DNA8. After comple-
tion of the total synthesis of schizandrin C and its region-isomer
(26, Fig. 5) the target compounds and synthetic intermediates9
were pharmacologically evaluated and a serendipitous compound,
DDB (27, Fig. 5), was found to be effective for protection against
the hepatotoxicity induced by carbon tetrachloride, thioacetamide,
and D-galactosamine in mice and rats.Please cite this article as: Guo Zongru. The modiﬁcation of natural products fo
10.1016/j.apsb.2016.06.003It is worth noting that DDB is one of the intermediates of the
unnatural compound 26, and exerts stronger activity than those of
25. However, the corresponding intermediate of schizandrin C (28,
Fig. 5) possesses much less activity than 27. It seems that the
relative positions of methoxy and methylene dioxy groups on the
biphenyl convey the effect of hepatoprotection. As expected,
compound 29 with altered disposition of the groups shows
intermediate activity (Fig. 5).
DDB (27) was selected as a candidate for clinical trials and
approved by the China Food and Drug Administration (CFDA) in
1997, named bifendate, and used as a liver-protecting drug for the
treatment of the patients with chronic hepatitis B.
To overcome the low solubility and poor biovailability of
DDB a second generation of liver-protecting drugs were devel-
oped. After systematic structural modiﬁcation and biological
evaluation, bicyclol (30, Fig. 5) was found to be superior to
bifendate both in pharmacological and pharmacokinetic proper-
ties. Different from the symmetrical structure of DDB, bicyclol
breaks the molecular symmetry and improves physico-chemical
properties and activity. Bicyclol was approved by CFDA
in 2001.r medical use. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/
Figure 7 Simplifying structures from trichostatin A to vorinostat.
The modiﬁcation of natural products for medical use 75.2. Diminishing chiral centers
5.2.1. From lovastatin to “statin” drugs
Lovastatin (31, Fig. 6), a cholesterol-lowering natural product, is
produced by certain higher fungi, such as Pleurotus ostreatus and
the closely related Pleurotus spp. The mechanism of action consists
of the reversible inhibition of 3-hydroxy-3-methylglutaryl-coen-
zyme A reductase (HMG-CoA reductase), an enzyme that catalyzes
the conversion of HMG-CoA to mevalonate. Mevalonate is a
required building block for cholesterol biosynthesis. Lovastatin
binds to and inhibits HMG-CoA reductase. Although lovastatin
was approved by US FDA in 1987 to be the ﬁrst hypolipidemic
agent, much research space remains for optimization10.
Lovastatin contains eight asymmetrical carbon atoms, two
located at the lactone moiety of the upper part and the others
distributed to the lower hexahydronaphthalene moiety as indicated
with red dots in structure 31. The lactone ring opens in cells by
enzymatic catalysis to form a (R,R)-β,δ-dihydroxypentanoic acid
moiety, which structurally mimics HMG and constitutes the
pharmacophoric feature. It is evident that the conﬁguration of
the two carbon atoms is crucial for binding to HMG-CoA
reductase. The lower part of the molecule binds to a hydrophobic
pocket and plays the inhibitory role. In fact, the chirality of this
part is unnecessary for binding. Based on the lovastatin structure,
several synthetic HMG-CoA reductase inhibitors have been
developed, such as simvastatin (32), ﬂuvastatin (33), atorvastatin
(34) and rosuvastatin (35), all of which contain the same fragment
(R,R)-β,δ-dihydroxypentanoic acid as in lovastatin (Fig. 6). The
hydrophobic moieties, however, are various and none of them has
asymmetric factors except simvastatin.
Crystallographic studies showed that the interactions between
the dihydroxypentanoic acid moieties of the statins and the
enzyme are mostly ionic or polar. The binding modes are similar
for all statin drugs. The rigid hydrophobic groups of the statins are
located in a shallow groove between helices Lα1 and Lα10 in the
same manner, though the scaffolds are different. It is worthwhile to
emphasize that atorvastatin and rosuvastatin contain carbamideFigure 6 Simplifying structures fr
Please cite this article as: Guo Zongru. The modiﬁcation of natural products fo
10.1016/j.apsb.2016.06.003and sulfonamide moieties, respectively, which form hydrogen
bonds with amino acid residues11. Only these two statins form
hydrogen bonds between Ser565 and a carbonyl oxygen atom or a
sulfone oxygen atom. Because of the hydrogen bond the thermo-
dynamic parameters of 34 and 35 are different from those of
others. The binding energy between rosuvastatin and the enzyme
are mainly contributed by enthalpy gain (ΔH: 76%, –TΔS: 24%),
for atorvastatin (ΔH: 39%, –TΔS: 61%), but for the other statins
the enthalpy contributes less than 20%. The hydrogen bonding
increases the speciﬁc binding12.5.2.2. From trichostatin A to vorinostat
Trichostatin A (36, TSA, Fig. 7), isolated from Streptomyces
hygroscopicus in the 1970s, was initially investigated as an
antifungal antibiotic. This linear polyketide was later found to be
a potent reversible inhibitor of histone deacetylases (HDAC).
HDACs' function is to remove acetyl groups from acetylated
histones. Another enzyme histone acetyltransferase (HAT) cata-
lyzes acetylation of histones to neutralize positive charges on their
tail regions, reducing their ability to bind DNA and thus loosening
the structure of chromatin. Whereas, HDACs remove acetyl
groups and HATs add them, the balance of these activities
modulates the transcriptional process. By inhibiting HDAC action,
trichostatin A mimics HAT activity, leading to hyperacetylation ofom lovastatin to “statin” drugs.
r medical use. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/
Zongru Guo8chromatin. HDAC is a target for anti-cancer and anti-inﬂammatory
therapy.
The ﬁrst US FDA-approved HDAC inhibitor was vorinostat
(37, SAHA, Fig. 7) in 2006 for the treatment of cutaneous T cell
lymphoma (CTCL) when the disease persists, gets worse, or
comes back during or after treatment with other medicines. At ﬁrst
glance, vorinostat seems to be a simpliﬁed version of TSA.
Actually, vorinostat originated not from TSA, but from the simple
organic molecule dimethyl sulfoxide (DMSO). Starting from
DMSO's induction of cell differentiation, Breslow and Marks
et al.13 40 years ago designed and evaluated aliphatic bifunctional
compounds using a phenotype screening model. By means of
medicinal chemistry and SAR analysis, hundreds of compounds
were investigated, from which vorinostat (37) was selected to be
developed as an anti-cancer agent. Comparing the structural
features of vorinostat with TSA, they have similar molecular
shape and length, and pharmacophoric distribution: the hydro-
xamic acid group at one end, and one hydrophobic phenyl ring at
the other end. Both compounds exhibit the same inhibitory activity
for HDACs. Crystallographic studies of the HDAC-vorinostat and
HDAC-TSA complexes indicate that the binding features of both
compounds are almost identical13.
As the proverb says “All roads lead to Rome”, the success of
vorinostat is independent of the natural product TSA, yet the target
and the mechanism of action of TSA provided the guide for
elucidating the molecular mechanism of vorinostat. On the other
hand, the simpliﬁed structure of vorinostat suggests the trans–
trans conjugated double bond and the chiral center of TSA are
unlikely to be necessary for the inhibition.
Entinostat (38, Fig. 7), a derivative of 2-aminophenyl benza-
mides, is a potent and orally-available inhibitor of HDACs. TheFigure 8 Simplifying structures from van
Please cite this article as: Guo Zongru. The modiﬁcation of natural products fo
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hydroxamic acid group and binds to the zinc binding area.
Entinostat has been widely investigated for the treatment of cancer
in phase III clinical trials14,15.5.3. Increasing activity or selectivity
5.3.1. From vancomycin to telavancin and dalbavancin
Vancomycin (39, Fig. 8) is a natural antibiotic used to treat a
number of bacterial infections. It is recommended intravenously as
a ﬁrst-line treatment for complicated skin and bloodstream
infections.
Being a large hydrophilic molecule, vancomycin is able to form
5 hydrogen bonds with the terminal D-alanyl-D-alanine moieties of
the N-acetylmuramic acid/N-acetylglucosamine (NAM/NAG)-pep-
tides under normal circumstances. The interactions prevent cell
wall synthesis of the long polymers of NAM and NAG that form
the backbone strands of the bacterial cell wall, and prevent the
backbone polymers that do manage to form through cross-linking
with each other. However, in resistant bacteria, the terminal D-ala
residue has been replaced by a D-lactate, so vancomycin cannot
bind, and cross-links are successfully formed.
To overcome resistance to vancomycin, second generation
drugs were developed. Telavancin (40, launched in 2009,
Fig. 8), a semisynthetic multifunctional lipoglycopeptide, disrupts
both cell wall synthesis and cell membrane integrity in methicillin-
resistant Staphylococcus aureus. It binds to the D-alanyl-D-alanyl
residues on the growing peptidoglycan chains and prevents
transpeptidation from occurring, preventing peptidoglycan elonga-
tion and cell wall formation. In the telavancin molecule a longcomycin to telavancin and dalbavancin.
r medical use. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/
The modiﬁcation of natural products for medical use 9aliphatic chain is introduced into the aminosugar moiety, which
anchors in the lipophilic bacterial membrane, thereby increasing its
stability in the target environment and its afﬁnity for peptidogly-
can. In addition, a polar fragment amino-phosphonic acid is linked
to the biphenyl moiety to balance the hydrophilic–lipophilic
properties. Telavancin was approved by the US FDA in 200916.
Another semisynthetic analog, dalbavancin (41, Fig. 8), was
launched in 2014. A similar lipophilic chain is also attached to the
aminosugar and functions in the hydrophobic interactions with the
cell membrane as described above. The modiﬁcation of other parts
in the molecule is to improve the afﬁnity and physico-chemical
properties17.5.3.2. From enkephalin to eluxadoline
Compounds that modulate opioid receptors (ORs) have long been
explored to search for analgesics. Morphine (8, Fig. 1C), as a mimic
of the endogenous pentapeptide enkephalin (42, Fig. 9), agonizes
ORs and has been a strong analgesic through history. Constipation,
one of morphine's adverse effects, is due to the activation of ORs in
the intestinal tract. Recently this “negative effect” has been become
appreciated as therapeutics for gastrointestinal motility modulation.
The ORs are categorized into three major subclasses, μ, δ, and
κ, with their classiﬁcations based on well-deﬁned pharmacologi-
cal proﬁles. Starting from enkephalin as the lead compound,
eluxadoline (43, Fig. 9) was developed as a dual modulatorFigure 9 Simplifying structures from enkephalin to eluxadoline.
Figure 10 The optimization fro
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bowel syndrome. Eluxadoline was approved by US FDA and
launched in 201518.
The main points in the modiﬁcation of enkephaline into
eluxadoline are outlined as follows: (a) to change the peptide
scaffold into a small organic molecule; (b) to increase chemical
and metabolic stability; (c) to avoid penetrating blood brain
barrier; (d) to remove the analgesic effect and addiction; (e) to
restrict locally to the gastrointestinal tract.
Fig. 10 concisely illustrates the optimization course from
enkephaline to eluxadoline. The N-terminal amido linkage of 42
is replaced by a tetrahydroisoquinoline moiety to limit the ﬂexible
conformation (42a). To avoid hydrolysis of the amide by
intramolecular nucleophilic attack of free amino group of 42a
the amido fragment is bioisosterically substituted by an imidazole
ring. Simultaneously, the phenylalanine amide is removed to yield
the dipeptidomimetic compound 42b. Optimizing the phenyl ring
of 42b affords 42c, which is separately cut at the two single bonds
of the tetrahydroisoquinoline to yield 42d. Alteration of R1 and R2
of 42d gives rise to the optimal scaffold 42e, in which R on phenyl
group is veriﬁed by various substituents to tune the selectivity for
μ and δ receptors. Finally eluxadoline (43) is validated as the ﬁnal
candidate. It is worthwhile to note that the presence of free
carboxyl and amino groups in 43 yield a zwitterion that prevents
the drug from being absorbed into the blood stream19.5.3.3. From himbacine to vorapaxar—proﬁt from chemical
syntheses
Himbacine (44, Fig. 11) is a piperidine alkaloid with a tricyclic
lactone scaffold isolated from Galbulimima baccata of Magnolia-
ceae in Australia. Since the discovery of himbacine in the 1960s,
half century has passed until vorapaxar (45, Fig. 11) was marketed
as an antithrombotic agent in 2014. The success of varapaxar is
attributable to the skilled methods of total synthesis and chemistry-
driven research and development, despite switching the project
target during the course of development.m enkephalin to eluxadoline.
r medical use. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/
Zongru Guo10Himbacine was originally investigated as an anti-Alzheimer
agent owing to the potent inhibitory activity on the M2 receptor
(Ki¼4.5 nmol/L) with a 10-fold selectivity over the M1 receptor.
In order to identify a therapeutically useful target, both the potency
and selectivity of himbacine needed to be optimized through a
rigorous structure–activity relationship study. A total synthesis of
himbacine was carried out as brieﬂy listed in Scheme 2.
The achievement of synthesis resulted in the design and
preparation of analogs with various scaffolds. Compounds 46
and 47 (Fig. 12) were synthesized for evaluating the inhibition of
the M2 receptor, but none of them showed activity, indicating that
the tricyclic lactone might be a pharmacophoric feature.
Keeping the tricyclic moiety constant, the piperidine part was
modiﬁed by various heterocyclic groups, and a new synthetic route
was designed as shown in Scheme 3 for preparing compound 48.
Compound 48, a gem-dimethyl pyrrolidine derivative of hib-
macine, possesses the same inhibition against M2 receptor as
himbacine. The activities of the N-ethyl compound or the
diastereomer of 48 notably decreased20.
Simultaneously, the compounds were evaluated for inhibition of
the thrombin receptor (protease activated receptor 1, PAR-1),
because himbacine exhibits strong antagonism on PAR-1. The
PAR-1 receptor is widely distributed on human platelets, endothe-
lial cells, and smooth muscle cells. Thrombin is the most potent
activator of platelets, and plays a critical role in the pathophysio–
logy of thrombosis. Activated platelets bind to ﬁbrinogen, causing
platelets to aggregate at the site of cardiovascular injury to form a
thrombus that is further stabilized by a thrombin-generated ﬁbrin
network. Since PAR-1 antagonists are expected to be speciﬁc forFigure 11 Simplifying structures from himbacine to vorapaxar.
Scheme 2 The concise scheme
Please cite this article as: Guo Zongru. The modiﬁcation of natural products fo
10.1016/j.apsb.2016.06.003the cellular activation of thrombin and do not inhibit ﬁbrin
generation, such an agent is likely to have less bleeding liability
than the currently-existing antithrombotic drugs.
Compound 49 (Fig. 13), a 6-methylpyridine-substituted analog,
was identiﬁed as a PAR-1 lead in a high-throughput assay
(IC50¼300 nmol/L). A new synthetic route was carried out to
prepare the congeners as illustrated in Scheme 4.
Structure–activity relationship studies led to the identiﬁcation of
the 5-phenyl-substituted analog 50 with higher activity. Com-
pound 50 (Fig. 14) was optically resolved and it was found that the
enantiomer with absolute chirality opposite to that of himbacine in
the tricyclic system was more active. The (þ)-50 compound with
an IC50 of 27 nmol/L is 10 times more active than the racemate. To
increase the metabolic stability of 43, several analogs with
substituents on the phenyl group were synthesized21.
A metabolic study on compound 50 by LC–MS/MS analysis
revealed that three pairs of hydroxylated diastereoisomers were
produced. One of the metabolites, the 7R-OH compound (51,
Fig. 14) was synthesized and showed 3 times more activity
(IC50 11 nmol/L) than that of 50. Compound 51 exhibits reason-
able bioavailability (F ¼ 30% and 50% for rats and monkey,
respectively) and stability. In the ex vivo platelet aggregation assay
in the cynomolgus monkey, 51 showed complete and sustained
inhibition of platelet aggregation at 3 mg/kg after oral administra-
tion. Compound 51 is the most potent PAR-1 antagonist reported
to date. However, it still showed a less than optimal clearance
proﬁle, owing to the generation of a considerable amount of 7,8-
dihydroxy metabolites. Therefore, 51 as a milestone compound
was modiﬁed by extensively incorporating heteroatoms into the C-of total synthesis of himacidine.
Figure 12 Structures of compounds 46 and 47.
r medical use. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/
Scheme 3 Synthetic scheme of compound 48.
Figure 13 Structures of compounds 49.
The modiﬁcation of natural products for medical use 11ring of the tricyclic motif and the terminal phenyl ring. In this
series, a benchmark compound, 52 (Fig. 14), showed a Ki of
4.5 nmol/L against PAR-1. In cynomolgus monkeys, 52 exhibited
an oral bioavailability of 62% at a dose of 3 mg/kg and the half-
life was 6.2 h following intravenous administration. Compound 52
was the ﬁrst candidate entered into preclinical trials22.
Simultaneously various derivatives of the C-7 amine were
explored with derivatization of the amine to the corresponding
amide, urea, sulfonamide, and carbamate. Among them, the
carbamate compound 45 showed a very promising proﬁle. Its
unique properties are underscored by the excellent oral bioavail-
ability in multiple animal species, high potency in a series of
in vitro functional assays, and potent oral activity in an ex vivo
cynomolgus monkey model of platelet aggregation. Compound 45
was 30 times more potent than the initial development candidate in
the series, showing complete obliteration of agonist-induced
platelet activation at 0.1 mg/kg with 424 h duration of activity
(versus comparable efﬁcacy at 3 mg/kg for the initial candidate
45). After a successful outcome in phase III clinical studies, 45
was approved by the FDA in 2014 as a new chemical entity (NCE)
for the treatment of for acute coronary syndrome and secondary
prevention of cardiovascular events in high-risk patients23.5.4. Increasing metabolic stability
5.4.1. From phlorizin to canagliﬂozin and other “gliﬂozins”
More than 99% of the plasma glucose that is ﬁltered in the kidney
glomerulus is reabsorbed. This reabsorption process is mediated by
two sodium-dependent glucose cotransporters (SGLTs): SGLT1, a
low-capacity, high-afﬁnity transporter expressed in the gut, heart
and kidney, and SGLT2, a high-capacity, low-afﬁnity transporter
that is expressed mainly in the kidney. Selective inhibition of
SGLT2 has been proposed to aid in the normalization of plasma
glucose levels in patients with diabetes by preventing the renal
glucose reabsorption process and promoting glucose excretion in
urine. Selective SGLT2 inhibitors would be desirable, since
gastrointestinal side effects associated with SGLT1 inhibition
would be minimized.Please cite this article as: Guo Zongru. The modiﬁcation of natural products fo
10.1016/j.apsb.2016.06.003The natural product O-glucoside phlorizin (53, Fig. 15) is a well-
documented, potent glucosuric agent that was subsequently shown to
be a nonselective SGLT inhibitor24. Because of its inhibition of
SGLT1 and also its poor metabolic stability due to its susceptibility
to β-glucosidase-mediated cleavage, 53, as a lead compound, was
modiﬁed in several respects: (a) altering its molecular structure to
increase the selectivity for SGLT2; (b) removing phenolic groups to
reduce phase 2 metabolism; (c) altering the O-glycoside link into a
C-glycoside to increase resistance to β-glucosidase.
Through a series of explorations, the structure activity relation-
ships of 53 were disclosed, and resulted in a general scaffold of
selective and potent SGLT2 inhibitors, such as formula 54 (Fig. 15),
which was characterized with C-aryl glucosides and meta-substituted
diarylmethanes. A number of compounds with preferred C-40 and C-
4 substitutions were synthesized and evaluated. Aryl groups A and B
were also replaced by heteroaromatic rings. Compound 55 (Fig. 15)
showed strong inhibition and selectivity against SGLT2 with an IC50
of 2.2 nmol/L over SGLT1 with IC50¼910 nmol/L (more than 400-
fold). Compound 48 exerted oral bioavailability in rats of F¼78%, a
half-life in plasma of 5 h, and pronounced anti-hyperglycemic effects
in high-fat diet-fed KK mice. Compound 55, named canagliﬂozin,
entered into clinical trials and was approved by the FDA in 2013 for
the treatment of type 2 diabetes mellitus25.
Almost at the same time, successive SGLT2 inhibitors were
launched (Fig. 15), including dapagliﬂozin (56)26, empagliﬂozin
(57)27, and ipragliﬂozin (58)28 in 2014, and tofogliﬂozin (59)29 is
in the phase III clinical trials.
The activity, selectivity, and bioavailability of these “gliﬂozins”
are listed in Table 1, indicating that all of these SGLT2 inhibitors
possess high selectivity and good absorption characteristics. It is
worth noting that compounds 48–52 were independently devel-
oped in different companies, and based on the common lead
compound O-glucoside phlorizin (53); the target molecules have
the same pharmacophore features and similar scaffolds.
5.4.2. From retinoic acid to tamibarotene
All-trans-retinoic acid (60, ATRA, Fig. 16) is a metabolite of
vitamin A (retinol) that mediates and induces growth and
differentiation of epithelial cells. ATRA acts by binding to and
activating the retinoic acid receptor (RAR); clinically ATRA is
indicated for the treatment of acute promyelocytic leukemia and
acne. However, serious adverse effects and its chemical instability
restrict its application. The structure of the conjugated polyene is
fast and easy to generate at room temperature. Structure–activity
relationships reveal that the pharmacophore of ATRA features a
polar group (carboxyl) at one end, a steric and hydrophobic moiety
at the other end, with a linker connecting them. Tamibarotene (61,
Fig. 16), an RAR agonist, is structurally quite different from that
of ATRA, yet it resembles the pharmacophore of ATRA: the
carboxyl group and the tetramethyltetraline moiety correspond to
trimethylcyclohexene part, the two phenyl rings include severalr medical use. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/
Figure 14 Pyridine-containing analogs.
Figure 15 Simplifying structures from phlorizin to canagliﬂozin and other “gliﬂozins”.
Scheme 4 Synthetic route of pyridine-containing analogs.
Table 1 Activity, selectivity and bioavailability of SGLT2 inhibitors.
No. Name SGLT2 IC50 (nmol/L) SGLT1 IC50 (nmol/L) Selectivity (fold) Bioavailability (%) Condition
55 Canagliﬂozin 2.2 910 414 78 Launched in 2013
56 Dapagliﬂozin 1.1 1390 1263 78 Launched in 2014
57 Empagliﬂozin 3.1 4 930 4300 490 Launched in 2014
58 Ipragliﬂozin 7.4 1880 254 71.7 Launched in 2014
59 Tofogliﬂozin 2.9 8444 2912 85 Phase III
Zongru Guo12double bonds, and the amide linkage makes the whole molecule
conjugated by p–π conjugation. Compound 61 is more active andPlease cite this article as: Guo Zongru. The modiﬁcation of natural products fo
10.1016/j.apsb.2016.06.003stable than 6030. Tamibarotene was approved by the FDA in 2005
for the treatment of acute promyelocytic leukemia31.r medical use. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/
Figure 16 Simplifying structures from retinoic acid to tamibarotene.
The modiﬁcation of natural products for medical use 139-cis-Retinoic acid (62, Fig. 16), an ATRA stereoisomer, is an
agonist of retinoid X receptor (RXR). Compound 55 was used to
treat Capocci sarcoma and dermatitis. The same poor stability
prompted modiﬁcation of the structure. Based on the same strategy
of ATRA modiﬁcation, bexarotene (63, Fig. 16) was designed and
developed. It is a chemically-stable agonist of the RXR and was
approved in 2000 to treat psoriasis and dermatitis32.
5.4.3. From patupilone to ixabepilone
Patupilone (64, epothilone B, Fig. 17) was originally identiﬁed as
one of the 16-membered polyketides produced by Soragium
cellulosum. Like paclitaxel, patupilone prevents cancer cells from
dividing by interfering with tubulin, because they share the same
binding site. Patupilone binds to the αβ-tubulin heterodimer
subunit. Once bound, the rate of αβ-tubulin dissociation decreases,
thus stabilizing the microtubules. Furthermore, it also causes cell
cycle arrest at the G2-M transition phase, thus leading to
cytotoxicity and eventually cell apoptosis33,34.
While patupilone showed potent antineoplastic activity in vitro,
this effect was not seen in preclinical in vivo models due to its poor
metabolic stability and unfavorable pharmacokinetics. The reason
is that it is subject to inactivation via esterase cleavage of the
lactone moiety. In medicinal chemistry amides, as bioisosters of
esters, generally possess signiﬁcant stability over ester groups. A
semisynthetic approach was taken to prepare analogs without this
liability. Ixabepilone (65, Fig. 17), the 16-aza-patupilone, showed
increased metabolic stability (t1/2¼52 h), potent tubulin polymer-
ization activity, and retained activity against paclitaxel-resistant
lines. Based on its shown efﬁcacy in clinical trials, ixabepilone
was approved by the US FDA in 2007 for the treatment of
aggressive metastasis of locally advanced breast cancer35.
Initially ixabepilone was prepared by a semi-synthetic method
starting from patupilone, which involved by Pd-catalysed opening
of the lactone bond, and through azide anion nucleophilic attack
on C15. The reduction of the azide yielded an amino compound,
which cyclized to ixabepilone, as brieﬂy shown in Scheme 536.
The ﬁrst total synthesis of epothilone was achieved by the
Danishefsky’s group37. The same group also realized the total
synthesis of ixabepilone38. One of the synthetic route is listed in
Scheme 6.
5.5. Improving physico-chemical properties
5.5.1. From artemisinin to dihydtoartemisinin, artemether,
artesunate, and artether
In search of new anti-malarial drugs against chloroquine-resistant
Plasmodium falciparum, a new natural product, artemisinin (1)
was discovered and isolated from Artemisia plant by Tu and her
co-workers in 1970 s. Artemisinin is a sesquiterpene containingPlease cite this article as: Guo Zongru. The modiﬁcation of natural products fo
10.1016/j.apsb.2016.06.0035 interweaving oxygen atoms to form a cyclic ether and a peroxy
ether, cyclic acetal and ketal, as well as a lactone. The special
scaffold and the presence of the peroxy moiety resulted in a new
mechanism of action and less cross-resistance for the inhibition of
plasmodia. Structure–activity relationships revealed that the per-
oxy group is a critical pharmacophoric feature. Reduction of the
peroxy moiety of 1 into an ether leads to loss of activity. However,
reducing the lactone moiety with NaBH4 under low temperature to
the hemiacetal affords dihydroatemisinin (66, Fig. 18), which
exerted stronger activities than did the lead compound 1, suggest-
ing that alterations in the lactone moiety retain or increase activity.
Given the absence of a solubilizing moiety in its structure,
artemisinin is insoluble in water, and poorly soluble in lipids. The
poor biopharmaceutic properties and low bioavailability of arte-
misinin restricts its clinical application. Li and co-workers39
synthesized hundreds derivatives of dihydroartemisinin with two
types of functional groups: ethers and esters. The methyl ether of
dihydroartemisinin (67, artemether, Fig. 18) showed strong
inhibitory activities in several plasmodia-infected animal models
and as a candidate entered into clinical trials in 1978. Artemether
was approved by the CFDA in 1987 as a new molecule entity and
launched in several formulations39.
To develop water-soluble artemisinin-related drugs for inject-
able formulations, dihydroartemisinin C10-monoesters of diacids
were designed and synthesized by Liu and co-workers40. One of
the compounds, succinic acid monoester (68, artesunate, Fig. 18)
possesses excellent antimalarial activity and physico-chemical
properties. Its sodium salt is soluble in water and suitable for
injection dosage. Clinical trials indicated that artesunate exerts a
signiﬁcant therapeutic effect for the treatment of patients with
tertiary falciparum and cerebral malaria. Artesunate was approved
by CFDA in 1987 as a new molecule entity and launched in
several formulations40.
Brossi et al.41 investigated dihydroartemisinin-C10-β-ethylether
(69, Fig. 18), which was developed by Brocacef Co. in The
Netherlands and launched in 2000. As a homolog of artemether
and a follow-up medicine, arteether does not show advantage over
artemether42.
Artemether, arteether, and artesunate are all prodrugs. These
molecules are rapidly hydrolyzed in plasma to dihydroartemisinin,
which is the active form and is rapidly conjugated to glucuronic
acid and excreted in the bile, resulting in short durations of action.
Moreover, dihydroartemisinin exerts some neurotoxicity.
To prolong the period of action and avoid the production of
dihydroartemisinin, a series of nitrogen-containing compounds
were synthesized. Compound 70 (Fig. 18), which has excellent
physico–chemical and pharmacological properties, was validated
to be a safe and effective antimalarial in aotus monkeys; the
compound, named artemisone, is now in a phase II clinical trial43.5.5.2. From indirubin to meisoindigo
The old Chinese traditional medicine Angelica-Aloe-Pill (Danggui
Luhui Wan) has been used for the treatment of chronic granulocyte
leukemia. Through systematic investigation of the six-ingredient
pill Qingdai, processed Indigofera tictoria was singled out as the
effective medicine of the pill. Indirubin (71, Fig. 19), in turn, was
found to have antileukemic active principles in this traditional
medicine44. Animal tests showed that indirubin exhibits inhibitory
activity against the growth of transplantable tumors. Clinically
indirubin is indicated for the treatment of chronic granulocytic
leukemia by oral administration. However, the adverse effects ofr medical use. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/
Scheme 5 The semisynthetic route of ixabepilone.
Scheme 6 The total synthesis of ixbepilone.
Figure 17 Simplifying structures from patupilone to ixabepilone.
Zongru Guo14indirubin on gastro-intestinal systems and poor bioavailability
prevent it from being widely applied45.
Indirubin is a 2,30-bis(dihydroindolone) compound. Its high
melting point (348–353 1C) and low solubility is attributed to the
planar structure and hydrogen bond with high lattice energy. To
break the intermolecular hydrogen, bond a series of N-alkyl
substituted indrubin were synthesized to optimize the balance
between the anti-cancer activity, solubility, and in vivo effects46.
Simultaneously, substituted isoindigo [3,30-bis(2,3-dihydro-2-oxoin-
dolylidene] compounds were also explored47. Among them com-
pound 72 (Fig. 19) with optimal activity and physico-chemical
properties was selected to be a candidate for clinical– trials.
Compound 72 is 3,30-bis(1-methyldihydro-2,20-dioxoindolydene),Please cite this article as: Guo Zongru. The modiﬁcation of natural products fo
10.1016/j.apsb.2016.06.003named meisoindigo, and proved to be an effective drug for chronic
myeloid leukemia and was approved by the CFDA in 1984.
Meisoinigo was also reported to have efﬁcacy in acute myeloid
leukemia (AML). In the AML cell lines, HL-60, NB4 and U937,
meisoindigo induces apoptosis in both caspase-dependent and
-independent pathways. The effect induced by meisoindigo is
likely to be mediated through the intrinsic mitochondrial pathway.
Meisoindigo also induces cell cycle arrest with more cells in sub-
G1 and G0/G1 phases and fewer cells in the S phase48.
Following the indirubin scaffold, Chan and co-workers49
optimized the solubility and the ability to penetrate into cells.
Compound 73 (Fig. 19), indirubin-3'-(2,3-dihydroxypropyl)-oxi-
mether, E804) exhibited potent angiosuppressive effects. Anr medical use. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/
The modiﬁcation of natural products for medical use 15in vitro study showed that E804 could signiﬁcantly inhibit human
umbilical vein endothelial cell proliferation, migration, and tube
formation in a concentration-dependent manner (0.4–40 μmol/L).
E804 would be a new potential candidate in the treatment of
angiogenesis-dependent diseases49.5.6. Synthesis-driven drug innovation: the platform for
tetracycline synthesis and the new antibiotic eravacycline
Since the ﬁrst tetracycline antibiotic aureomycine (74, Table 2) was
discovered in 1948, all tetracyclines approved for human or
veterinary use today are fermentation products or are derived from
fermentation products by semi-synthesis. The market of both natural
and semi-synthetic tetracyclines (74–81) is listed in Table 2.Table 2 The structure of natural and semi-synthetic tetracyclines.
ACD B
OH
O OH
H H
O
H
O
NMe2
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NH2
OH
R1R2 R3R4
567
8
9
10
H3
H3
74–80
No. Name R1 R2 R3
74 Aureomycine Cl CH3 OH
75 Terramycine H CH3 OH
76 Tetracycline H CH3 OH
77 6-Demethyltetracycline H H OH
78 6-Deoxytetracycline H CH3 H
79 Doxycycline H CH3 H
80 Minocycline N(CH3)2 H H
81 Tigecycline –
Figure 18 Simplifying structures from artemisinin to dihydtoartemi-
sinin, artemether, artesunate, and artether.
Figure 19 Simplifying structures from indirubin to meisoindigo.
Please cite this article as: Guo Zongru. The modiﬁcation of natural products fo
10.1016/j.apsb.2016.06.003The early synthesis of sancycline (6-deoxy-6-demethyltetracy-
cline) was realized by Woodward and coworkers50 in 1962,
Strategically, the route developed by Woodward for the synthesis
employed a “left-to-right” or D-A mode of construction. With
the beneﬁt of more than 50 years of structure–activity relationship
data, as well as X-ray crystal structures of tetracycline bound to the
bacterial ribosome, the left-to-right mode of construction used in
these pioneering synthetic efforts can be seen to present a practical
disadvantage to the discovery of new tetracycline antibiotics,
because the D ring has emerged as one of the most promising
sites for structural variation. This was a primary consideration
guiding Myers and co-workers to assemble tetracyclines by a
convergent coupling of D- and AB-ring precursors. The AB plus D
strategy for tetracycline synthesis by C-ring construction is shown
to be robust across a range of different carbocyclic and hetero-
cyclic D-ring precursors, proceeding reliably and with a high
degree of stereochemical control. A series of tetracyclines with
various substitutions on the phenyl ring or the heteroaromatic rings
(D ring) were synthesized to explore potent and anti-MRSA
antibiotics. Among them, eravacycline (75, Table 2) and 7-
ﬂuorotetracycline exhibited broad spectrum antibacterial activity
and are now in phase III clinical trials.
The synthetic process utilizes two key intermediates in a
convergent approach as concisely shown in Scheme 7. The key
transformation is a Micheal–Dieckmann reaction between a
suitable substituted aromatic moiety (82a, D-ring) and a key
cyclocyclohexanone derivative (82b, AB-ring) to give rise to 82c
with a desired conﬁguration. Subsequent deprotection (82d) and
hydrogenation to open the isooxazole ring (82e), and then
acylation yields the target molecule eravacycline. As a platform
for tetracycline synthesis, this technology gives access to a broad
range of molecules that would be inaccessible by semi-synthetic
methods and provides a powerful engine for the discovery and
development of new tetracycline antibiotics51.
5.7. Protecting resource and environment: development of
houttuynium
Developing medicines cannot be at the sacriﬁce of natural resources
and the environment. The research and development of theOH
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Scheme 7 The brief synthetic route of eravacycline.
Scheme 8 The synthetic route of houttuynium.
Zongru Guo16antibacterial agent houttuynium is an example. In folklore medicine,
Houttuynia Cordala is topically used for the treatment of colpitis of
women. The plant is not available in the winter seasons. In 1970,
the scientists at Institute of Materia Medica, Chinese Academy of
Medical Sciences (CAMS), extracted the volatile oil from Houttuy-
nia Cordala and identiﬁed compound 83 (Fig. 20) as the main
component of the oily mixture by GC–MS.
Starting from simple organic materials, the preparation of 83 was
easily realized as shown in Scheme 8. To increase the stability 83
(a liquid) was transformed to the sodium bisulﬁte adduct (84, Fig. 20)
as white crystals. After preclinical and clinical trials, 84, named
houttuynium, was approved by the CFDA as an anti-infectious drug52.6. Brief remarks
The secondary metabolites of living organisms do not exist for the
healthcare of human beings. Although the natural products are
normally valuable lead compounds, seldom can they be directly used
in clinical applications. Structural modiﬁcations are necessary and
involve several aspects. The strategy for structural modiﬁcation is to
increase potency and selectivity, to improve physico-chemical, bio-
chemical, and pharmacokinetic properties, to eliminate or reducePlease cite this article as: Guo Zongru. The modiﬁcation of natural products fo
10.1016/j.apsb.2016.06.003adverse effects, to simplify the structural complexity, including
removal of redundant atoms and chirality while retaining activities,
and to generate patentable compounds. To accomplish these multi-
dimensional operations, sophisticated syntheses and skillful preparation
of complicated molecules are essential. Mutual cooperation and
interaction between organic and medicinal chemists play an essential
role in modifying natural products for commercial use through drug
research and development.
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